---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009936"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:14:20.968229+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q4 net loss widens to $9.2M; revenue up 11%; FDA approval for CGuard Prime expected H1 2025

## Summary
- Q4 revenue rose 10.7% YoY to $1.95M; gross profit fell 7.1% to $469K as COGS grew faster.
- Net loss widened to $9.17M ($0.19/sh) from $5.41M ($0.16/sh); operating expenses surged 56% to $9.84M.
- Full-year 2024 revenue $7.01M (+13% YoY); net loss $32.0M ($0.76/sh) vs $19.9M ($0.82/sh).
- Cash and marketable securities $34.6M at Dec 31, 2024, down from $39.0M a year earlier.
- Submitted PMA to FDA for CGuard Prime; enrolled first patients in CGUARDIANS II TCAR study; expects US approval H1 2025.

## SEC filing metadata
- accession: 0001493152-25-009936
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/0001493152-25-009936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009936
- JSON: https://secwatch.observer/filing/0001493152-25-009936.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.